News

Advanced Preventive Screening with Dr. Melissa O'Meara

At the March 5 Wellness Series event, Dr. Melissa O'Meara recently spoke about advanced preventive screening and the rapidly evolving landscape of modern medicine. Today’s patients have access to an unprecedented amount of personal health information. With the right tools, individuals can monitor sleep patterns, track heart rate variability, measure glucose levels in real time, and even review reports describing variations in their genetic code.

This explosion of data reflects a remarkable moment in biomedical history. At the same time, it presents a new challenge for both patients and clinicians. With so many emerging technologies and tests available, how can we distinguish evidence-based preventive medicine from well-marketed but unproven screening tools? And once we obtain complex biological data, how should it influence our health decisions?

Understanding advanced preventive screening requires a careful look at what preventive medicine is, what lies beyond routine care, and how new data should be interpreted.
 

What Is Preventive Medicine?

Preventive medicine focuses on reducing illness and death by identifying health risks before symptoms appear. In the United States, most preventive care recommendations are guided by organizations such as the U.S. Preventive Services Task Force, which reviews large amounts of population-level evidence to determine whether specific screenings reduce major health outcomes such as mortality or serious disease.

Routine preventive care includes screening for common chronic conditions such as high blood pressure, cholesterol disorders, elevated blood sugar, and osteoporosis. Early detection and treatment of these conditions can help prevent complications like heart attacks, strokes, and chronic kidney disease.

Routine cancer screenings are another key component of preventive care. Mammograms, Pap smears, PSA testing, colonoscopies, and chest CT scans for high-risk smokers help detect several of the most common cancers in the United States. Together, these cancers account for roughly half of all new cancer diagnoses each year. These screening tools are supported by extensive outcome data and are recommended by organizations such as the American Cancer Society.

The defining feature of a validated screening test is not simply that it identifies abnormalities. It must also demonstrate that detecting those abnormalities leads to improved health outcomes.

Most preventive care occurs during visits with a primary care physician. Sometimes screening happens in subtle ways. A physician may walk a patient to the door after an appointment not only as a courtesy, but also to observe coordination and walking speed. These small observations can provide important information about neurological health and physical function.

At a minimum, most adults should see their doctor once a year, complete the five major recommended cancer screenings, and have routine blood work at least every five years if they have no chronic conditions. Many clinicians recommend annual blood testing to provide a clearer picture of overall health.
 

Moving Beyond Routine Care

Once routine screening has been addressed, the conversation often shifts toward newer and emerging technologies. These tools can provide additional information about health risks, but they also introduce more uncertainty.

Continuous glucose monitoring is one example. These wearable devices provide detailed, real-time information about blood sugar levels. They are essential for people with diabetes, but they are increasingly used by individuals without diabetes who are interested in optimizing metabolic health.

Early research suggests that fluctuations in glucose levels may have metabolic implications. However, strong long-term evidence demonstrating health benefits for people with normal blood sugar levels is still limited. For some individuals, continuous glucose monitoring encourages healthier dietary and lifestyle choices. For others, the constant stream of data may increase anxiety without changing behavior.

Whole-body MRI scans represent another emerging screening tool. These scans have the potential to detect hidden cancers or vascular disease in people without symptoms. However, when used in large populations with low disease prevalence, the likelihood of incidental findings increases significantly.

In simple terms, these scans almost always detect something. Many of those findings ultimately prove to be harmless. This phenomenon is known as overdiagnosis. Detecting abnormalities that would never cause harm can lead to additional imaging, invasive procedures, and unnecessary stress without improving long-term outcomes.

There are certain populations that clearly benefit from whole-body MRI screening. Individuals with hereditary cancer syndromes such as Li-Fraumeni syndrome are a well-known example. Interestingly, the largest study of direct-to-consumer MRI screening found that many participants reported positive psychological effects. About 72 percent said they felt reassured after testing, and 83 percent felt they gained useful insight into their health. For some people, peace of mind carries its own value.

Another rapidly developing technology is the liquid biopsy, sometimes called a multi-cancer early detection test. These blood tests analyze circulating tumor DNA or other molecular signatures that may indicate the presence of cancer.

The biological concept is compelling. Detect cancer before it becomes clinically apparent. However, important questions remain. Sensitivity for early-stage disease varies, and false-positive results may occur even when no cancer can be found.

Earlier detection seems intuitively beneficial, but medical history shows that this is not always the case. In certain cancers, including cervical and prostate cancer, aggressive screening in the past sometimes led to unnecessary biopsies and treatments without improving survival.

Current liquid biopsy tests are often better at detecting later-stage cancers than very early disease, and their predictive value remains relatively low in the general population. For these reasons, they are not currently recommended as routine screening for everyone. They should never replace established cancer screenings such as mammograms, colonoscopies, Pap smears, or PSA testing. Still, the technology continues to evolve rapidly and may play a larger role in preventive care in the future.

Genetic testing for hereditary cancer risk is another area gaining attention. A 2023 study published in JAMA Oncology found that up to one in eight cancer patients carries an inherited genetic variant linked to cancer risk. Among those individuals, 42 percent did not have a family history that suggested inherited risk.

Another study published in the Annals of Internal Medicine suggested that screening all adults at age 30 for certain high-impact genetic conditions could be cost-effective. These conditions, known as CDC Tier 1 genomic conditions, include familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and Lynch syndrome. For these conditions, early identification and treatment can significantly reduce illness and death.

These targeted genetic tests are different from direct-to-consumer whole genome sequencing products. Many consumer genetic tests provide interesting information, but their findings are not always clinically actionable.

Physician-ordered tests such as MyRisk from Myriad and genetic risk panels offered through Labcorp can help determine whether someone has an increased risk for specific hereditary conditions. In many cases, consultation with a genetic counselor can help patients decide whether testing is appropriate.

Genetic and antibody testing also highlight an important principle in medicine. Genes are not destiny. Many tests provide insight into risk rather than confirming disease. The usefulness of any test depends heavily on the individual’s baseline risk before testing begins.
 

Why Screening Must Be Interpreted Carefully

The most important question in preventive medicine is not whether something can be measured. It is whether measuring it improves outcomes that matter.

Every screening test must be evaluated based on its sensitivity, specificity, positive predictive value, and the patient’s baseline risk. Predictive value depends heavily on disease prevalence. Even highly accurate tests can produce false positives when used in low-risk populations.

False-positive results can lead to diagnostic cascades that include additional imaging, biopsies, and procedures. Each step carries potential risks.

The psychological effects of screening also matter. Risk information is inherently probabilistic. Some people feel empowered by learning about their risks. Others may experience persistent anxiety after receiving uncertain results.

For a screening test to be clinically useful, it should lead to a meaningful change in management. A positive result should answer a practical question. What will change tomorrow because of this information? If the answer is nothing, the value of that test becomes less clear.
 

A Thoughtful Approach to Preventive Screening

Modern medicine has entered a remarkable era of innovation. Physicians can now sequence genomes, measure coronary artery calcium, detect fragments of tumor DNA in the bloodstream, and monitor metabolic signals continuously.

These technologies hold real promise for improving health and extending lifespan. However, scientific rigor requires careful evaluation. The ability to measure something does not automatically translate into improved health outcomes.

Preventive screening should focus on delivering the greatest overall clinical benefit. The goal is not to detect every possible abnormality, but to reduce suffering, extend healthy lifespan, and provide clear guidance for better decision making.

In this new era of advanced testing, more data are not always better. Better decisions are better.

For clinicians and researchers working in preventive medicine, the challenge is to understand how these new technologies can be used thoughtfully and responsibly. That work is ongoing, and it is driven by a commitment to improving the health of the communities they serve.
 

---